Analysts Offer Insights on Healthcare Companies: Xilio Therapeutics (XLO) and Neurocrine (NBIX)
TipRanksNov 9, 2023 18:52 ET
Promising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio Therapeutics
TipRanksNov 7, 2023 06:26 ET
Chardan Capital Sticks to Its Buy Rating for Xilio Therapeutics (XLO)
TipRanksMay 30, 2023 08:35 ET
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target
BenzingaMay 30, 2023 05:17 ET
Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target
BenzingaMay 11, 2023 04:47 ET
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating
MT NewswiresJan 27, 2023 11:55 ET
Xilio Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 27, 2023 10:46 ET
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $10
Benzinga Real-time NewsJan 27, 2023 10:46 ET
Xilio Therapeutics Analyst Ratings
Benzinga Analyst RatingsDec 21, 2022 06:22 ET
Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7
Benzinga Real-time NewsDec 21, 2022 06:22 ET
Raymond James Adjusts Price Target on Xilio Therapeutics to $13 From $31, Maintains Outperform Rating
MT NewswiresNov 10, 2022 10:21 ET
Xilio Therapeutics Analyst Ratings
Benzinga Analyst RatingsNov 10, 2022 04:22 ET
Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $13
Benzinga Real-time NewsNov 10, 2022 04:22 ET
Xilio Therapeutics analyst ratings
Benzinga Analyst RatingsAug 10, 2022 10:04 ET
Morgan Stanley Maintains Overweight on Xilio Therapeutics, Lowers Price Target to $20
Benzinga Real-time NewsAug 10, 2022 10:04 ET
Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $20 From $32, Reiterates Overweight Rating
MT NewswiresAug 10, 2022 08:49 ET
No Data
No Data